The first test worldwide for the determination of serum auto-antibodies against Amyloid peptides, developed by DRG!
DRG Amyloid beta ELISA kits are solid phase enzyme-linked immunosorbent assays (ELISA) based on the sandwich principle.
Benefit of DRG Amyloid beta ELISAs
Amyloid auto-antibodies are supposed to regulate the concentration of Amyloid beta (Aβ) peptides in the body, which might be helpful to protect against Alzheimer´s disease. The DRG ELISA is the first test worldwide for the determination of serum auto-antibodies against Amyloid peptides. Already today IVIG (Intravenous Immunoglobulin) - the purified IgG fraction of human plasma - is used as therapeutics in the field of several neurological disorders.
Serum, plasma or CSF contains Amyloid beta peptides of different size. Amyloid beta (1-40) containing 40 amino acids are the most abundant Aβ peptides, while the concentration of Aβ 1-42 is approximately 10 times lower. Due to its outstanding sensitivity, the DRG Elisa Abeta (1-40) specifically detects 1-40 peptides not only in CFS, but also in serum and plasma samples.
The lyophilized standards just have to be resolved in distilled water. All other reagents are ready-to-use.
The combination of both ELISAs can offer insight into the correlation and mutual influence of Aβ (1-40) peptides and their corresponding auto-antibodies.